Condition: De Novo Multiple Myeloma · Anitocabtagene Autoleucel · Sponsor: PETHEMA Foundation
The goal of this clinical trial is to learn if anitocabtagene autoleucel following induction therapy works to treat adult participants with newly diagnosed multiple myeloma. The main objectives of this clinical trial are: * To determine the incidence and severity of all adverse events (AEs). * To determine the proportion of patients achieving undetectable minimal residual disease (uMRD) negative-CR rate (minimum 10 to -5) at 12 months (+/- 3 months) after enrollment. Participants will receive induction therapy with a quadruplet regimen including a proteasome inhibitor (Bortezomib \[V\]), immunomodulatory drug (Lenalidomide \[R\]), dexamethasone \[d\] and anti-CD38 monoclonal antibody (Daratumumab \[D\] or Isatuximab \[Isa\]) followed by anitocabtagene autoleucel. Participants in Cohorts A and B will receive lenalidomide maintenance therapy following infusion with anitocabtagene autoleucel.
This description comes directly from the study's public registry record.
Carmen López-Carrero · 0034 699 835 437 · carmen@fundacionpethema.es
Roberto Maldonado · 0034 683 15 66 87 · roberto.maldonado@fundacionpethema.es
Always discuss trial participation with your own doctor first.
| Hospital Germans Trias i Pujol (ICO BADALONA) | Badalona, Spain | Recruiting |
| H. Clinic de Barcelona | Barcelona, Spain | Recruiting |
| H. 12 de Octubre | Madrid, Spain | Recruiting |
| H. Ramón y Cajal | Madrid, Spain | Recruiting |
| Clinica Universidad de Navarra | Pamplona, Spain | Recruiting |
| Hospital Clinico Universitario Salamanca | Salamanca, Spain | Recruiting |
| H. Marqués de Valdecilla | Santander, Spain | Recruiting |
| C H Santiago de Compostela | Santiago de Compostela, Spain | Recruiting |
| Complejo Hosp. Regional Virgen del Rocío | Seville, Spain | Recruiting |
| Hospital Universitario y Politécnico La Fe de Valencia | Valencia, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07045909